NCT02248090View on ClinicalTrials.gov

AZD9496 First Time in Patients Ascending Dose Study

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

October 22, 2014

Primary Completion Date

January 31, 2017

Study Completion Date

April 3, 2019

Conditions
ER+ HER2- Advanced Breast Cancer
Interventions
DRUG

AZD9496

AZD9496

DRUG

AZD9496

If initial dosing of AZD9496 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose or maximum feasible dose is defined

Trial Locations (6)

10065

Research Site, New York

34232

Florida Cancer Specialists, Sarasota

37203

Sarah Cannon, Nashville

110-744

Seoul National Univ. Hospital, Seoul

CB2 0QQ

Research Site, Cambridge

M20 4BX

Christie, Manchester

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY